Could KIM-1 and NGAL levels predict acute kidney injury after paracentesis? – preliminary study

Renal Failure

Jerzy Chudek¹  Jan Duława²  Michał Holecki³  Maciej Migacz³  Marta Pietrukaniec³  Agnieszka Żak-Gołąb³  Magdalena Olszanecka-Glinianowicz⁴ 

[1] Department of Internal Diseases and Oncological Chemotherapy, Medical Faculty in Katowice, Medical University of Silesia;Department of Internal and Autoimmune Diseases, School of Health Science, Medical University of Silesia;Department of Internal, Autoimmune and Metabolic Diseases, Medical Faculty in Katowice, Medical University of Silesia;Department of Pathophysiology, Medical Faculty in Katowice, Medical University of Silesia;

关键词: acute kidney injury;    liver cirrhosis;    ngal;    kim-1;    paracentesis;   

DOI  :  10.1080/0886022X.2020.1801468

来源: DOAJ

【 摘 要 】

Background Kidney dysfunction is a common complication in patients with severe liver cirrhosis. There is a need for discovery and validation of novel biomarkers for earlier AKI detection. The aim of this study was to determine if tubular injury markers: NGAL and KIM-1 could be helpful in the early diagnosis of AKI in patients undergoing therapeutic paracentesis. Methods This preliminary study included 24 adult patients diagnosed with liver cirrhosis who had been hospitalized due to massive ascites requiring paracentesis. Pre- and post-paracentesis plasma samples were taken from each patient and biomarkers were measured. Results Before paracentesis, the levels of serum and urinary NGAL were similar between patients and controls; while urinary KIM-1 was markedly increased in liver cirrhotic patients (0.76 vs. 0.24 ng/ml; respectively). Although urinary NGAL levels in AKI patients were 5-time greater than in non-AKI subgroup, the difference did not reach statistical significance (13.2 vs 1.5 pg/mL, p = 0.06). Serum NGAL level, post-procedure, was 3 times greater in AKI subgroup. Conclusion Kidney injury markers, especially serum NGAL, may be useful for the early detection of AKI. However, further research is required to determine if biomarkers of kidney injury may help identify patients with cirrhosis who would most likely benefit from early AKI prevention and treatment.

【 授权许可】

Unknown